Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand.
Eur J Heart Fail. 2009 Sep;11(9):832-9. doi: 10.1093/eurjhf/hfp099. Epub 2009 Jul 15.
Mechanisms for clearance of circulating amino-terminal pro-brain natriuretic peptide (NT-proBNP) remain poorly understood and are relevant to the clinical utility of NT-proBNP as a diagnostic and prognostic biomarker in cardiovascular disorders. We sought to determine site(s) of production and clearance of plasma NT-proBNP in the human circulation.
In 120 subjects undergoing clinically indicated cardiac catheterization, blood samples were collected from arterial and multiple venous sites to measure transorgan gradients of plasma NT-proBNP. Clearance of plasma NT-proBNP occurred across kidney, liver, musculoskeletal, and head and neck tissues. Proportions of calculated total body NT-proBNP clearance were 55-65% across the kidney, 20-25% across the liver, 10-15% across musculoskeletal tissue, and 5-10% across the head and neck. Renal fractional extraction of NT-proBNP was unrelated to estimated glomerular filtration rate. Transorgan gradients, reflecting both renal and extra-renal NT-proBNP degradation, were correlated across multiple clearance sites within an individual.
Plasma NT-proBNP is cleared by multiple tissues in the human circulation with approximately 55-65% of total clearance occurring in renal tissue. These data provide the first evidence for extra-glomerular clearance of NT-proBNP and suggest a common multisite clearance mechanism subject to generalized regulation. Renal NT-proBNP extraction was sustained in the face of even moderate levels of kidney dysfunction.
循环中氨基末端脑利钠肽前体(NT-proBNP)的清除机制仍不清楚,这与 NT-proBNP 作为心血管疾病诊断和预后生物标志物的临床应用有关。我们试图确定人循环中血浆 NT-proBNP 的产生和清除部位。
在 120 名接受临床指征性心导管检查的受试者中,从动脉和多个静脉部位采集血液样本,以测量血浆 NT-proBNP 的跨器官浓度梯度。血浆 NT-proBNP 的清除发生在肾脏、肝脏、肌肉骨骼和头颈部组织。计算得出的全身 NT-proBNP 清除率的比例分别为肾脏 55-65%、肝脏 20-25%、肌肉骨骼组织 10-15%和头颈部 5-10%。NT-proBNP 的肾分馏提取与估计肾小球滤过率无关。反映肾内和肾外 NT-proBNP 降解的跨器官浓度梯度在个体内的多个清除部位之间相关。
人循环中的血浆 NT-proBNP 被多个组织清除,其中约 55-65%的总清除率发生在肾脏组织中。这些数据首次提供了 NT-proBNP 肾小球外清除的证据,并表明存在一种普遍受调节的多部位清除机制。即使在中度肾功能障碍的情况下,肾脏对 NT-proBNP 的提取也能持续进行。